Funder
National Natural Science Foundation of China
Shenyang Pharmaceutical University
Reference36 articles.
1. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge;Alexander;P t,2016
2. Anti-PD-1 therapies—a new first-line option in advanced melanoma;Sullivan;Nat. Rev. Clin. Oncol.,2015
3. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now;Bellmunt;Cancer Treat Rev.,2017
4. Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells;Zhong;Oncol. Rep.,2017
5. Immunotherapy comes of age in lung cancer;Khanna;Clin. Lung Cancer,2017